Descargar - Úlceras.net

170 ■ PIE DIABÉTICO27. Lázaro JL, March JR, Torres de Castro OG, Segovia T,Guadalix G. Guía de tratamiento del Pie Diabético conTerapia de Presión Negativa. 2006.28. Löndahl M, Fagher K, Katzman P. What is the role of hyperbaricoxygen in the management of diabetic foot disease?Curr Diab Rep 2011;11:285-93.29. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The Role ofHyperbaric Oxygen in the Treatment of Diabetic FootUlcers. Angiology 2011;25 (In Press).30. O’Reilly D, Linden R, Fedorko L, Tarride JE, Jones WG,Bowen JM, Goeree R. A prospective, double-blind, randomized,controlled clinical trial comparing standardwound care with adjunctive hyperbaric oxygen therapy(HBOT) to standard wound care only for the treatmentof chronic, non-healing ulcers of the lower limb inpatients with diabetes mellitus: a study protocol. Trials2011;7:69.31. Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A,Wasem J. The importance of growth factors for the treatmentof chronic wounds in the case of diabetic foot ulcers.GMS Health Technol Assess 2010;6:12.32. Wu SC, Marston W, Armstrong DG. Wound care: the roleof advanced wound healing technologies. J Vasc Surg2010;52:59S-66S.33. Dubský M, Jirkovská A, Bém R, Pagácová L, Fejfarová V, VargaM, et al. Treatment of critical limb ischemia and diabeticfoot disease by the use of autologous stem cells. Vnitr Lek2011;57:451-5.34. Schulz GS, Mast BA. Molecular analysis of the enviroment ofhealing and chronic wounds: cytokines, proteases andgrowth factors. Wounds 1998;10:1-14.35. Ling X, McLennan SV, Lo L, Natfaji A, Bolton T, Liu Y, et al.Bacterial Load Predicts Healing Rate in NeuropathicDiabetic Foot Ulcers. Diabetes Care 2007;30:378-80.36. Loot MA, Kenter SB, Au FL, Van Galen WJ, Middelkoop E,Bos JD, et al. Fibroblasts derived from chronic diabeticulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol2002;81:153-60.37. Bennet NT, Schultz GS. Growth factors and healing.Biochemical properties of growth factors and their receptors.Am J Surg 1993;165:728-37.38. Lázaro JL, García E, Beneit JV, Martínez de Jesús FR, AragónFJ. Estudio Aleatorizado y comparativo de un apósito decolágeno y celulosa oxigenada regenerada en el tratamientode úlceras neuropáticas de pie diabético. Cir Esp2007;82:27-31.39. Ghatnekar O, Willis M, Persson U. Cost-effectiveness ostreatring deep diabetic foot ulcers with Promogran in fourEuropean countries. J Wound Care 2002;11:70-4.40. Lázaro JL, Aragón FJ, García E, Beneit JV, González M. ARestrospective Análisis of the Cost-Effectiveness of aCollagen/Oxidized Regenerated Cellulose Dressing in theTreatment of Neuropathic Diabetic Foot Ulcers. OstWound Management 2010;56:4-8.41. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K,et al. Angiogenic gene therapy for experimental critical limbischemia: acceleration of limb loss by over expression ofvascular endothelial growth factor 165 but not of fibroblastgrowth factor-2. Circ Res 2002;90:966-73.42. Kloth LC. Electrical stimulation for wound healing: a reviewof evidence from in vitro studies, animal experiments, andclinical trials. Int J Low Extrem Wounds 2005;4:23-44.43. Goldman R, Rosen M, Brewley B, Golden M. Electrotherapypromotes healing and microcirculation of infrapoplitealischemic wounds: a prospective pilot study. Adv SkinWound Care 2004;17:284-94.44. Ferroni P, Roselli M, Guadagni F, Martini F, Mariotti S,Marchitelli E, et al. Biological effects of a software-controlledvoltage pulse generator (PhyBack PBK-2C) on therelease of vascular endothelial growth factor (VEGF). Invivo 2005;19:949-58.45. Marinel·lo J. Abordaje integral de la cicatrización de las heridascrónicas e importancia de la nutrición. En Nuevasestrategias para mejorar y acelerar la cicatrización:Balnimax®. ISBN: 978-84-7429-520-7. Barcelona, 2011.46. Verdú J. Evidencias científicas sobre la actividad del ácido -lipoico y presentación de nuevos estudios. En Nuevasestrategias para mejorar y acelerar la cicatrización:Balnimax®. ISBN: 978-84-7429-520-7. Barcelona, 2011.47. Padrós C. Acción de un complemento alimenticio a base deácido -lipoico en el tratamiento de las úlceras neuropáticas.En Nuevas estrategias para mejorar y acelerar la cicatrización:Balnimax®. ISBN: 978-84-7429-520-7. Barcelona, 2011.